Clinical Study

A Study To Evaluate Nyx-458 In Subjects With Mild Cognitive Impairment Associated With Parkinson's Disease

Posted Date: Jan 14, 2020

  • Investigator: Michael Keys
  • Specialties: Memory Disorders, Movement Disorders, Parkinson's Disease
  • Type of Study: Drug

The objective of the study is to evaluate the safety and tolerability of multiple dose levels of NYX- 458 in subjects with mild cognitive impairment associated with Parkinson’s disease (MCI-PD), and to explore the potential benefit of NYX-458 on cognition


50 To 80 Years Of Age, Diagnosis Of Parkinson’S Disease, And Diagnosis Of Mild Cognitive Impairment Associated With Parkinson’S Disease


Parkinsons, Mild Cognitive Impairment

For More Information:

Marcelle Shidler, Ma

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.